Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heparinase III HLGAG fragments and uses thereof

Inactive Publication Date: 2005-10-20
MASSACHUSETTS INST OF TECH
View PDF0 Cites 77 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] It has been discovered, according to one aspect of the invention, that expression of heparinases does not necessarily represent a switch from a primary tumor to a metastatic diseased state. Consistent with the current paradigm, heparinase I activity was found to accelerate tumor growth and correlate with increased metastasis. Surprisingly, heparinase III, however, was found to inhibit primary tumor growth and significantly reduce metastasis. Thus, in one aspect the invention is a method for preventing growth o

Problems solved by technology

Although the structure and chemistry of HLGAGs are fairly well understood, information on how specific HLGAG sequences modulate different biological processes has proven harder to obtain.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heparinase III HLGAG fragments and uses thereof
  • Heparinase III HLGAG fragments and uses thereof
  • Heparinase III HLGAG fragments and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

DEPC Inactivates Heparinase III

[0190] As a first step towards identifying histidines that are critical for the enzymatic activity of heparinase III, the effect of the modification reagent DEPC on the enzymatic activity of heparinase III was determined. DEPC is a common reagent used for the determination of catalytically critical histidines in enzymes. As stated in early publications (Godavarti, R., Cooney, C. L., Langer, R., and Sasisekharan, R. (1996) Biochemistry 35, 6846-52 and Shriver, Z., Hu, Y., and Sasisekharan, R. (1998) J. Biol. Chem. 273, 10160-67), DEPC is useful for the determination of catalytically critical histidines, however care needs to be taken to ensure that other nucleophilic residues, namely tyrosines, lysines, and cysteines are not modified.

[0191] Heparinase III was incubated with 0.31 (□), 0.54 (●), 0.97 (◯), 1.5 (σ), 1.9 (Δ) mM DEPC at pH 6.5 and at 25° C. (shown in inset of FIG. 1). The natural log of the percent activity remaining was plotted versus an a...

example 2

Peptide Mapping of the Histidine Modified by DEPC

[0200] To identify the histidine(s) modified by DEPC that resulted in the loss of enzymatic activity, DEPC-modified heparinase III was digested with Lys-C. Peptides that had altered retention times and an increased in absorbance at 240 nm as compared to a control digest were collected and sequenced (FIG. 5). Three peptides had altered retention times and increased absorbance at 240 nm were isolated and sequenced. Two of the peptides contained histidine 295 and one contained no modified histidine residues.

[0201] Labeling of the DEPC-reactive histidines was completed by first reacting heparinase III with DEPC, then denaturing the protein in urea. Following an overnight digest with Lys-C, the resultant peptides were separated by using a 1.6%-78.4% acetonitrile gradient over 120 minutes, which included a 5 min isocratic phase (1.6% acetonitrile, 0.1 % trifluoroacetic acid) at the beginning of the run. Lys-C peptides were monitored at 21...

example 3

Site-Directed Mutagenesis of Heparinase III

[0202] In parallel to the mapping studies and to confirm the results of the chemical modification experiments, each of the thirteen histidine residues present in heparinase III was mutated to alanine. The recombinant heparinase III mutant proteins were expressed, purified, and assessed for enzymatic activity towards heparan sulfate (Table 2).

TABLE 2Kinetic Constants for r-heparinase III and the Histidine Mutants.EnzymeKM (uM)akcat (s−1)wild-type8078r-heparinase IIIH36A9886H105ANDbNDbH110A937H139A19168H152A5883H225A8022H234A7523H241A165H295ANDNDH424A5924H469A71100H510ANDNDH539A92132

aCalculated assuming a molecular weight for heparan sulfate of 15 kDa.

bProtein expression levels were too low for heparinase III kinetic assay.

[0203] As a control, the r-heparinase III construct without its putative signal sequence was expressed. The concentration and purity of all recombinant enzyme preparations were determined using SDS-PAGE. The recombinan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Therapeuticaaaaaaaaaa
Login to View More

Abstract

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and / or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Description

RELATED APPLICATIONS [0001] This application is a divisional of U.S. Ser. No. 10 / 291,337, filed Nov. 8, 2002 and currently pending, which is a divisional of U.S. Ser. No. 09 / 802,285, filed Mar. 8, 2001 and currently pending, which application claims priority under 35 U.S.C. §119 from U.S. provisional application Ser. No. 60 / 187,846, filed Mar. 8, 2000, the entire contents of all of which are incorporated herein by reference.GOVERNMENT SUPPORT [0002] Some aspects of the invention were made with government support under NIH Contract No. GM57073. The government may have certain rights in the invention.FIELD OF THE INVENTION [0003] The invention relates to heparinase III and mutants thereof. In particular, the invention relates to modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing HLGAGs from a solution, inhibition of angiogenesis, inhibiting coagulation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/726A61K38/00A61K38/51C12N15/09A61K45/00A61K47/48A61K48/00A61P9/00A61P17/06A61P27/02A61P35/00A61P35/04C08B37/00C08B37/10C12N9/24C12N9/88C12N15/60C12P19/26C12P19/28C12Q1/34C12Q1/527
CPCA61K31/726A61K38/51C08B37/0075C12N9/88C12P19/26C12Q1/527Y10S530/811G01N2500/02G01N2333/988A61K31/00A61K2300/00A61P17/06A61P27/02A61P35/00A61P35/04A61P9/00
Inventor LIU, DONGFANGPOJASEK, KEVINSHRIVER, ZACHARYHOLLEY, KRISTINEEL-SHABRAWI, YOSUFVENKATARAMAN, GANESHSASISEKHARAN, RAM
Owner MASSACHUSETTS INST OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com